We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

101 hedge funds and large institutions have $856M invested in Avadel Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more capital invested

Capital invested by funds: $443M → $856M (+$413M)

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

42% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 24

9% more funds holding

Funds holding: 93 → 101 (+8)

5.7% more ownership

Funds ownership: 78.39% → 84.1% (+5.7%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

7% less call options, than puts

Call options by funds: $21.6M | Put options by funds: $23.1M

Holders
101
Holders Change
+8
Holders Change %
+8.6%
% of All Funds
1.59%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
25
Increased
34
Reduced
24
Closed
17
Calls
$21.6M
Puts
$23.1M
Net Calls
-$1.53M
Net Calls Change
-$14.2M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$34.8M
2
RI
RTW Investments
New York
+$13.9M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$9.04M
4
JMPWA
JP Morgan Private Wealth Advisors
California
+$6.5M
5
KCM
Knoll Capital Management
Florida
+$6.5M

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$13.9M
2
Bank of America
Bank of America
North Carolina
-$8.44M
3
SB
Samsara BioCapital
California
-$5.74M
4
PA
Perceptive Advisors
New York
-$5.4M
5
ACM
Altium Capital Management
New York
-$4.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Soleus Capital Management
Connecticut
$5.06M +$3.99M +307,000 New
PCM
27
Portolan Capital Management
Massachusetts
$4.78M +$20.6K +1,581 +0.5%
AR
28
Advisory Research
Illinois
$4.45M +$3.51M +270,077 New
Ameriprise
29
Ameriprise
Minnesota
$4.31M +$534K +41,084 +19%
Jane Street
30
Jane Street
New York
$4.25M +$3.02M +232,151 +896%
DMKJ
31
David M. Knott Jr
$3.97M -$656K -50,484 -17%
Deutsche Bank
32
Deutsche Bank
Germany
$3.71M +$2.92M +225,000 New
Goldman Sachs
33
Goldman Sachs
New York
$3.51M +$2.09M +160,431 +306%
EWM
34
Edge Wealth Management
New York
$2.47M -$260K -20,000 -12%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$2.15M -$2.6M -199,903 -61%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$2.1M +$1.65M +127,293 New
Two Sigma Advisers
37
Two Sigma Advisers
New York
$2.05M +$244K +18,800 +18%
CSS
38
Cubist Systematic Strategies
Connecticut
$1.72M +$719K +55,289 +112%
VCIM
39
Velan Capital Investment Management
Georgia
$1.65M +$965K +74,257 +288%
SC
40
Schulhoff & Co
Ohio
$1.58M – – –
IAMOG
41
Investors Asset Management of Georgia
Georgia
$1.55M -$479K -36,831 -28%
CIBC Private Wealth Group
42
CIBC Private Wealth Group
Georgia
$1.54M -$644K -49,575 -35%
Geode Capital Management
43
Geode Capital Management
Massachusetts
$1.33M +$5.19K +399 +0.5%
Commonwealth Equity Services
44
Commonwealth Equity Services
Massachusetts
$1.26M +$418K +32,150 +72%
CM
45
Caption Management
Oklahoma
$1.11M -$628K -48,311 -42%
SC
46
Shay Capital
New York
$1.09M +$858K +66,000 New
BlackRock
47
BlackRock
New York
$880K +$80.4K +6,185 +13%
MCM
48
MAI Capital Management
Ohio
$845K +$667K +51,270 New
MML Investors Services
49
MML Investors Services
Massachusetts
$834K +$201K +15,500 +44%
Barclays
50
Barclays
United Kingdom
$813K +$641K +49,335 New
1
2
3 4 5

AVDL Hedge Fund Activity: Q2 2023 in Review

101 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2023, worth a combined $856M — up 93% from $443M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new AVDL positions and 17 closed out — a net gain of 8 holders — while 34 added to existing stakes and 24 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $34.8M. The largest seller was Cowen and Company, cutting an estimated $13.9M.

  • 101 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2023, up from 93 in Q1 2023.
  • Funds reported $856M of Avadel Pharmaceuticals stock for Q2 2023, up 93% quarter-over-quarter.
  • 25 funds opened new Avadel Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +8 holders.
  • The largest Avadel Pharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $34.8M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2023 was Cowen and Company, an estimated $13.9M sold.

Based on aggregated 13F filings for Q2 2023.